Several members of the nuclear receptor superfamily including RXR (retinoid X receptor) bind to a specific retinoic acid response element (site A) of the apoAI promoter. However, transcriptional activation of the apoAI gene by different homo-and heterodimeric forms of RXR or RAR (retinoic acid receptors) cannot be evaluated in mammalian cells, which contain endogenous RXR or RAR. In order to circumvent this limitation, we assessed the DNA-binding activities and transcriptional activation of different homo-and heterodimers of these receptors in yeast. Electrophoretic mobility shift assays (EMSA) demonstrated that yeast expressed RARα does not bind to site A of the apoAI promoter, whereas binding of RARβ to site A is ligand-dependent. Both RARα and RARβ form heterodimers with RXRα and bind to site A with high affinity. These DNA-binding studies correlate with the transcriptional data, which indicated that RARβ but not RARα activates transcription from site A in response equally well to 9-cis and all-trans retinoic acids. 9-cis RA is a more potent ligand than all-trans RA to activate transcription via RXR/RAR heterodimers. We conclude that this yeast expression system is a useful tool to elucidate the 'transactivaton code' for apoAI site A via specific combinations of different homo and heterodimeric versions of RXR and RAR.
INTRODUCTION
All-trans and 9-cis isomers of retinoic acid are potent modulators for a broad spectrum of essential biological activities including embryogenesis, cell proliferation and differentiation (1, 2) . Thus, this class of compounds has received considerable attention for their pharmacological utilities. Although some of these retinoids are potential drugs for the treatment of dermatological diseases and cancers, their toxicities including teratogenicity have limited their therapeutic values. The pleiotropic action of retinoids is mediated by different homo-or heterodimeric versions of retinoic acid/retinoid X receptors, which belong to the nuclear receptor superfamily of ligand activated transcription factors (3, 4) . Each of these receptors has three distinct subtypes namely RARα,β,γ and RXRα,β,γ, which form heterodimers with each other (5) . Furthermore, these receptor subtypes also have isoforms, which can generate theoretically 48 different RXR/RAR heterodimeric forms (2) . It is highly suggestive that the undesirable side effects of retinoids are in part due to the formation of homo-and heterodimers of these receptor subtypes or isoforms, which modulate the expression of different target genes in response to the same or different naturally occurring retinoids. Therefore, ligands which are selective for certain receptor subtypes in conjunction with a specific target gene can be exploited as beneficial drugs with fewer side effects.
Regulation of the apoAI gene, which encodes apolipoprotein AI, the major protein constituent of HDL, is controlled by synergistic interactions between several transcription factors bound to three distinct sites (sites A, B and C) of a liver specific enhancer located between nucleotides -222 to -110 upstream of the transcription start site (+1) (6) . In mammalian cells, RXRα homodimers activate transcription via site A (-214 to -192) of the apoAI gene in response to 9-cis RA but not to all-trans RA, whereas RXRα/RARα heterodimers activate transcription via this DNA element in response to both 9-cis RA and all-trans RA (7) . However, the transcriptional activation by retinoic acid receptor (RARα,β,γ) homodimers in response to 9-cis RA/alltrans RA is still unclear due to the presence of endogenous RXR or RAR subtypes present in mammalian cells. We have reported previously that RXRα homodimers bind to site A and function as ligand-dependent transcriptional activators in yeast cells, which are devoid of endogenous RXR/RAR or enzymes that convert all-trans RA to 9-cis RA (8) . In this report, we further utilized this retinoid-responsive transcription unit to assess the DNA-binding properties, differential transcriptional activation and ligand responsiveness exhibited by different homo-and heterodimeric versions of RXR/RAR in yeast using site A as the retinoic acid responsive element (RARE). Our results demonstrate that this yeast expression system is a useful genetic tool to define the 'transactivation code' for site A via specific combinations of homo-and heterodimeric versions of RXR and RAR as well as to unravel systematically the synergistic interactions between these transcription factors. Furthermore, this microbial system can be used to identify unambiguously selective ligands capable of transactivating the apoAI gene via different RXR/RAR homoor heterodimers.
MATERIALS AND METHODS

Yeast strains
The Saccharomyces cerevisiae strain used was BJ2168 as described previously (8) (9) (10) . Growth and transformation of yeast cells were performed according to standard procedures (11) . Double and triple transformant yeast strains were grown in synthetic drop-out media to maintain expression plasmids.
Construction of yeast expression and reporter plasmids
The human RARα and RARβ genes were amplified by polymerase chain reaction (PCR) to possess an EagI site 5′ and a BssHII site 3′ to their coding sequences and were cloned into the yeast expression vector, YEp351, which has been modified to carry the CUP1 promoter (9,12) and a synthetic linker containing EagI and BssHII restriction sites downstream of the ubiquitin gene (9, 10) . The resultant expression plasmids, YEp c RARα and YEp c RARβ which contain the inducible CUP1 promoter driving the ubiquitin-receptor fusion genes and the LEU2 gene as the auxotrophic marker were used to transform yeast strains carrying the reporter plasmid in the absence or presence of the RXRα expression plasmids (YEpRXRα) as described previously (8) . The reporter plasmid (YEpA) contains two copies of site A upstream of the CYC1 promoter, which is fused to the lac-Z gene of E.coli (8) (9) (10) 
Western blot analysis
Yeast transformants carrying the RARα or the RARβ receptor expression plasmid were grown overnight in synthetic drop out medium in the absence or presence of 100 µM cupric sulfate until the cell density reached late log phase (OD = 1.0 at 600 nm). Cells were harvested and yeast extracts were prepared according to standard protocols (8, 9, 12) . Protein samples were electrophoresed on 10% SDS-PAGE, electroeluted onto nitrocellulose and probed with a polyclonal antiserum raised against human RARα or RARβ obtained from Santa Cruz Biotechnology, Inc. (CA).
Electrophoretic mobility shift assays (EMSA)
The procedures for EMSA and labeling of probes have been described previously (8, 9) . Briefly, double-stranded oligonucleotide corresponding to site A was labeled with [ 32 P]dATP by filling in reaction with Klenow enzyme. The labeled oligo site A (30 000 c.p.m./reaction) was incubated with yeast extract in 20 µl of a reaction mixture, which contains 7.5% glycerol, 0.05% NP-40 and 1 µg of poly (dI-dC). Protein concentrations of yeast extracts were normalized by adding bovine serum albumin. The reaction mixture was incubated at room temperature for 20 min. For antibody supershift assays, 1 µl of antiserum against RXRα, RARα or RARβ was incubated with the reaction mixture at room temperature for 30 min prior to addition of 32 P-labeled oligo site A. Bound and free DNAs were separated on a 6% non-denaturing gel. In some cases, yeast extracts were incubated with 9-cis RA or all-trans RA (1 µM) at 4_C for 1 h prior to EMSA. To determine the dissociation constants (K d ) of retinoic acid receptor homo-versus heterodimers for site A, a constant amount of yeast extracts containing these transcription factors were incubated with an increasing concentration (0.25 to 25 nM ) of 32 P-labeled probe (site A) as described previously (9) . The bound and free radioactivity were determined from the autoradiogram using a betascope. The data were converted into Scatchard plot analysis (13) .
Hormone binding assays
To determine the hormone binding properties of yeast expressed retinoic acid receptor homodimers or heterodimers, yeast extracts containing these receptors were incubated at 4_C overnight with 5 nM of [ 3 H]9-cis RA in the absence (total binding) or presence (non-specific binding) of 100-fold molar excess of radioinert 9-cis RA. Specific binding was determined by subtracting non-specific from total binding. Bound and free radioactivity were separated by dextran-coated charcoal suspension as described previously (12) . The binding affinity of the receptors for [ 3 H]9-cis RA was determined by Scatchard plot analysis (13) .
Transcription assay
Double transformant yeast strains were grown in synthetic medium in the absence of tryptophan and uracil whereas triple transformant yeast strains were grown in synthetic medium in the absence of tryptophan, uracil and leucine. For receptor induction, 100 µM of cupric sulfate was added to the medium during cell inoculation. When cell density reached late log phase, yeast cells were assayed for β-galactosidase induction as described previously (8-10).
RESULTS
Retinoic acid receptor (RARα and RARβ ) expression in yeast
In the present study, the expression of the human RARα and RARβ was under the control of a regulated promoter, CUP1, which could be induced by cupric sulfate, whereas the RXRα gene was driven by the constitutive promoter, TDH3 as described previously (8, 10) . As shown in Figure 1 , Western blot analysis revealed a distinct 55 kDa protein in yeast extracts prepared from the yeast strain carrying the RARα expression plasmid under induced conditions (+Cu) (lane 3). This immunoreactive band was not detected in the same yeast strain without the expression plasmid (lane 1) or without copper induction (lane 2). The other band with a molecular mass of ∼48 kDa is a non-specific immunoreactive protein, which is present in the parent yeast strain. Using a polyclonal antibody against human RARβ, an immunoreactive band with a molecular mass of 52 kDa was detected in yeast extracts prepared from the yeast strain carrying the RARβ expression plasmid only under induced conditions (+Cu) (data not shown). 
RXRα/RARα heterodimer formation
One important observation in our previous studies is that yeast expressed RXRα homodimers bind to site A of the apoAI enhancer in the absence of 9-cis RA. In the present study, the DNA-binding properties of homo-or heterodimeric versions of yeast expressed RXRα/RARα were examined by electrophoretic mobility shift assays (EMSA). As shown in Figure 2 (left panel), when 5 µl of yeast extracts (7.0 µg protein) prepared from yeast strains carrying expression plasmids for RXRα (yRXRα) or RARα (yRARα) were incubated with a 32 P-labeled doublestranded DNA probe containing site A, a distinct retardation complex formation, which could be supershifted with an anti-RXRα polyclonal antibody was observed only for yRXRα (lanes 1 and 2) but not for yRARα (lane 3). We have previously shown that yeast extracts prepared from parental yeast strain carrying no expression plasmid did not have any endogenous factor that binds to site A (8) . In order to rule out the possibility of receptor inactivation at low protein concentrations, bovine serum albumin (BSA) was added in the subsequent binding mixtures to normalize protein concentrations and we have found that the degree of retardation complex formation was the same in the presence or absence of BSA. When 1 µl (0.6 µg protein) of yeast extracts containing either RXRα alone (yRXRα) or RARα alone (yRARα) was incubated with the site A probe, there was no retardation complex formation (Fig. 2: right panel, lanes 1 and 2) . A distinct protein-DNA complex was detected when these two extracts were mixed with the probe (lane 3). This heterodimeric complex formation could be displaced by 100-fold molar excess of radioinert oligo A (lane 4) and could be supershifted with an anti-RXRα polyclonal antibody (lane 5).
To further examine RXRα/RARα heterodimer formation in vivo, an increasing concentration of yeast extracts (1, 3 and 8 µg protein) (Fig. 3, lanes 1-3 and lanes 6-8) prepared from the triple transformant yeast strain in which the expression of RARα is under the control of a regulated promoter, CUP1 as described previously were analysed by EMSA. Without copper induction However, an increasing complex formation (RXRα/RARα heterodimers) could be detected in yeast extracts with copper induction (+Cu) with an increase in protein concentrations from 1 to 8 µg (compare lanes 1 and 6; lanes 2 and 7; lanes 3 and 8). The heterodimeric complexes from lane 8 could be supershifted with either RXRα or RARα antisera (lanes 9 and 10). Thus, these observations together with the data described in Figure 2 indicate that yeast expressed RXRα and RARα form heterodimers very efficiently. The inability of yeast-expressed RARα to bind apoAI site A supports the previous studies, which clearly show that RARα by itself does not bind to any retinoic acid response elements (7, 15) .
RARβ homodimer and heterodimer formation
In vitro binding of RARβ homodimers to site A was examined by EMSA. When 5 µl (15 µg protein) of yeast extracts (yRARβ) containing RARβ was incubated with 32 P-labeled site A probe, there was no complex formation (Fig. 4, lane 5) . However, retardation complex formations were apparent when the yeast extracts were preincubated with 9-cis RA or all-trans RA at 4_C for 30 min prior to EMSA (Fig. 4, lanes 6 and 7) . This ligand-dependent DNA-binding property of RARβ homodimers is in contrast to the ligand-independent DNA-binding properties of yeast expressed RXRα homodimers (8) and hepatic nuclear factor 4 (HNF-4) (9). To demonstrate RXRα/RARβ heterodimer formations, we performed mixing experiments as described previously in Figure 2 . When 0.2 µl (0.6 µg protein) of yeast extracts containing either RXRα (yRXRα) or RARβ (yRARβ) was analyzed by EMSA, there was no retardation complex formation (Fig. 4, lanes 1 and 2) . However, a distinct protein-DNA complex, which could be supershifted with the RXRα antiserum was observed when the same volume of extracts containing RXRα or RARβ were mixed with the probe (Fig. 4,  lanes 3 and 4) . These complexes could also be supershifted with the RARβ antiserum (data not shown). This heterodimer formation was not affected by 9-cis RA or all-trans RA (data not shown). Thus, these DNA-binding studies demonstrate that RARβ homodimers bind to apoAI site A only in the presence of 9-cis RA or all-trans RA, whereas RXRα/RARβ heterodimers bind to site A in the absence of ligands.
To demonstrate RXRα/RARβ heterodimer formation in vivo, we performed similar experiments as described in Figure 3 to analyze the triple transformant yeast strain by EMSA. As shown in Figure 5 , a gradual increase of complex formation was detected when the amount of yeast extract was increased. However, more retardation complexes were observed under induced conditions (+Cu) as comparing to non-induced conditions (-Cu) (compare lanes 1, 2 and 3 versus lanes 6, 7 and 8) . The formation of homoand heterodimers was also supported by antibody supershifting experiments (lanes 4, 5, 9 and 10). We have consistently observed that the complex formed in lane 8 is greatly attenuated by incubating the binding mixture with RARβ antibody with the formation of a weak supershift complex. This data might indicate (i) weak binding between RARβ antibody and the heterodimeric complex since the epitope located at the carboxyl end of the RARβ is also the region that forms heterodimer with RXRα, (ii) the binding of RARβ antibody to RARβ carboxyl end blocks the heterodimer formation with RXRα. Thus the latter observation strongly suggests that the complex detected in lane 8 represents RXRα/RARβ heterodimers. 
Differential DNA-binding affinities of homo-versus heterodimers of RXR/RAR for site A
One major complexity of the retinoid signaling pathway is that RXR forms heterodimers not only with RAR subtypes, but also with vitamin D receptor, thyroid hormone receptor, the orphan receptors such as peroxisome proliferator activated receptor (PPAR) and the COUP transcription factor (16, 17) . In fact, the heterodimer formation with RXR is a prerequisite for these transcription factors to bind to their target DNA sequences efficiently (18, 19) . Whether these heterodimers can exhibit target gene activation in response to the same ligands as for the homodimers is an area of intense interest. Since the relative potency of target gene activations exhibited by these transcription factors is determined partly by their affinities for target DNA sequences, we examined the differential binding affinities of homo-and heterodimeric versions of retinoic acid receptors for site A by Scatchard analysis. As shown in Figure 6A and B, the binding affinities (K d ) of RXRα/RARα, RXRα/RARβ heterodimers for site A are 3.1 and 4.0 nM respectively, whereas the K d obtained for RARβ homodimers is 10.4 nM (Fig. 6C) , which is similar to that reported for RXRα homodimers (9) . Although it has been shown that the efficiency of DNA binding of RXRα/RARα heterodimers is much higher than that of RXRα homodimers (16, 17) , this is the first time that we quantitatively demonstrate RXR/RAR heterodimers bind to site A with a higher affinity than RXR or RAR homodimers.
To determine whether yeast-expressed RARα and RARβ were able to bind 9-cis RA, we performed saturation analysis with [ 3 H]9-cis-RA. Scatchard plot analysis of RARα and RARβ homodimers revealed K d values of 0.4 and 0.3 nM respectively (data not shown). Taken together, our data indicate that RARα and RARβ produced in yeast cells have the following characteristics similar to those observed for the in vitro synthesized proteins: (i) they bind 9-cis RA with an affinity characteristic of a hormone receptor, (ii) RARα does not bind to site A unless it heterodimerizes with RXRα, whereas RARβ binds to site A only in the presence of 9-cis RA or all-trans RA.
Differential transcriptional activation by homo-and heterodimers in yeast
To examine the transcriptional activation of apoAI site A by homo-and heterodimeric versions of RXR and RAR in yeast, we transformed the yeast strains expressing these receptors with a reporter plasmid containing two copies of apoAI site A as the enhancer and analyzed the reporter enzyme (β-gal) induction in response to 9-cis RA or all-trans RA. For RXRα homodimers, we used the double transformant yeast strain, which expressed RXRα constitutively as described previously (8) whereas RARα or RARβ homodimers were expressed under the CUP1 promoter. As shown in Figure 7 , the three homodimers exhibited distinct hormone responsiveness to the two naturally occurring retinoids. 9-cis RA is very specific for the transcriptional activation of RXRα homodimers, whereas RARβ activates transcription in response equally well to both 9-cis RA and all-trans RA. In contrast, RARα did not exhibit any transcriptional activity in the presence of these two ligands. The β-gal activities detected for RARα homodimers are similar to those observed for the yeast strain carrying only the reporter plasmid (YEpA) (data not shown).
To analyze the transcriptional activations of RXRα/RARα and RXRα/RARβ heterodimers, the triple transformant yeast strains (YEpRXRα/YEp c RARα/YEpA or YEpRXRα/YEp c RARβ/ YEpA) were tested for hormone responsiveness. Under non-induced conditions (-Cu), the two triple transformant yeast strains exhibited hormone responsiveness characteristic of RXRα homodimers, i.e. responsive only to 9-cis RA (Fig. 8) . Under induced conditions (+Cu) where heterodimer formation is favored, the triple transformant yeast strains responded to 9-cis RA and to a less extent, all-trans RA. RXRα/RARβ heterodimers also exhibited low constitutive transcriptional activity in the absence of ligands.
DISCUSSION
It has been shown that in vitro synthesized RAR does not bind to retinoic acid response elements (RAREs) even in the presence of 9-cis RA (7). However, transient cotransfection studies using CV1 cells indicated that RARα homodimers could activate transcription from RAREs of the CRBP1, RARβ2 and apoAI genes in response both to 9-cis RA and all-trans RA (20) . It is now apparent that this discrepancy is due to the presence of endogenous RXR in mammalian cells, which form heterodimers with RAR leading to ligand-dependent transcriptional activation. The apoAI site A is a complex RARE, which binds to several members of the steroid/thyroid receptor superfamily including RXR, RAR, and the orphan receptor, hepatic nuclear factor 4 (HNF-4) (18, 19) . One important observation in our previous studies is that yeast expressed RXRα homodimers bind to site A of the apoAI enhancer in the absence of 9-cis RA, but transactivates a yeast basal promoter linked to site A only in the presence of 9-cis RA (8) . As an on going investigation of the 'transactivation code' for specific combinations of RAR homoand heterodimers on site A of the apoAI gene, we expressed different homo-and heterodimers of RAR/RXR in yeast strains carrying the site A reporter plasmid and examined their DNAbinding properties and transcriptional activity.
Our EMSA studies clearly indicate that RARα does not bind to site A, whereas RARβ binds to site A only in the presence of 9-cis RA or all-trans RA. These DNA-binding studies were further supported by the transcription activation experiments which demonstrated that RARα did not exhibit ligand-dependent transcriptional activation, whereas RARβ transactivated site A equally well in response to 9-cis RA or all-trans RA. These observations are in contrast to mammalian cell (CV1) cotransfection studies, which indicated that RARα but not RARβ transactivated site A of the apoAI gene in response to both 9-cis RA or all-trans RA (20) . Whether this discrepancy is due to the presence of tissue specific factors that heterodimerize with RARα or RARβ in CV1 cells remains to be determined. However, it has been demonstrated quantitatively by immunoprecipitation, the presence of RXRα, RARα and RARγ in HeLa cells, HepG2 cells and MCF-7 cells (21) . RARβ has also been shown to transactivate the thyroid response element (TREpal) carrying an inverted repeat of AGGTCA in yeast cells in response primarily to all-trans RA and weakly to 9-cis RA (22) . Both RARα and RARβ form heterodimers with RXRα very efficiently. Furthermore, saturation analyses indicated that these heterodimers bind to site A with an affinity two to three times higher than those observed for RARβ or RXRα homodimers (9) . These differential DNAbinding affinities correlate quite well with the transcriptional activation potency exhibited by different homo-and heterodimeric versions of RXR/RAR. 9-cis RA is a more potent ligand than all-trans RA for both heterodimers. Similar hormone responsiveness was observed for RXRγ/RARγ heterodimers in yeast cells carrying the reporter plasmid containing a retinoid response element (βRE) derived from the promoter of the RARβ gene (23) . In contrast, all-trans RA is the potent ligand for RXR/RAR heterodimers when TREpal is used as the cis-acting element in yeast cells (22) . Thus, 9-cis RA and all-trans RA can activate a wide variety of target genes via different combinations of homoand heterodimeric versions of RAR/RXR, leading to diversified biological responses. Although RXRα/RARα and RXRα/RARβ heterodimers exhibit higher affinity binding for apoAI site A, we cannot rule out the possibility that the hormone responsiveness to different retinoids in this system is contributed by both homo-and heterodimers. However, we have detected several synthetic compounds (non-retinoids) from our chemical library that can activate RXRα/RARα heterodimers but not RXRα/RARβ heterodimers or RXRα homodimers in this yeast expression system (unpublished observation) indicating the usefulness of this yeast-based assay to detect selective ligands for the retinoid receptor superfamily.
Although yeast expressed RARα does not bind to site A, it binds to the radioactive ligand, [ 3 H]9-cis RA with an affinity (K d = 10 -10 M) similar to that observed for RXRα and RARβ produced by yeast cells. This observation indicates that binding of a specific ligand to a receptor and target gene activation by the same ligand are two distinct molecular events. It has also been shown that the ecdysone receptor, another member of the nuclear receptor superfamily, does not bind to its natural ligand, 20-OH ecdysteroid or muristerone A unless it heterodimerizes with another nuclear factor, Ultraspiracle (usp), the insect homologue of RXR (24) . Taken together, the reconstitution of RXR/RAR and other nuclear receptor functions in yeast (8) (9) (10) 12, 15, 22) has allowed us to redefine the complexity of signal transduction pathways exhibited by the nuclear receptor superfamily. Thus, target gene activation can be achieved by four different classes of nuclear receptors. The first class belongs to the classical steroid hormone receptors (androgen, progesterone or estrogen), as well as RXRα and RARβ homodimers, which are ligand-activated transcription factors. In contrast, RARα homodimers bind ligands but can not transactivate a target gene unless they heterodimerize with RXRα. The third class of nuclear receptor is the ecdysone receptor, which requires the presence of its heterodimeric partner, usp to bind hormone and subsequently for target gene activation (24) . The last group of nuclear receptor is the ill-defined 'orphan receptors', which have not been associated with a specific ligand. These orphan receptors can function as ligand-independent transactivators such as hepatic nuclear factor 4 (HNF-4) (9, 19) or repressors such as apolipoprotein regulatory protein 1 (ARP-1) (25).
In conclusion, the observation that site A is also a target for RARβ homodimers suggests an important role of all-trans RA in the regulation of the apoAI gene as opposed to our initial belief that its isomeric form, 9-cis RA is the major active ligand to upregulate the apoAI gene (25, 26) . Furthermore, the present studies clearly indicate that this yeast expression system is a powerful tool to identify selective ligands for different homo-and heterodimeric versions of RXR/RAR in combination with different RAREs.
